Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775603 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL12160014 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL12160056 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL18475635 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL12160094 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| Hydrochloric Acid SCHEMBL19689541 | 0.98 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| Hydrochloric Acid SCHEMBL21531494 | 0.98 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| Hydrochloric Acid SCHEMBL22613427 | 0.98 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL9284198 | 0.98 | MAPK13 (0.47) | MAPK13MAPK12MAPK11MAPK14SCN10A | |
| SCHEMBL9280936 | 0.98 | MAPK13 (0.47) | MAPK13MAPK12MAPK11MAPK14SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503557-A | A kind of industrialized preparing process of his Wei key intermediate of Dacca | 常州吉恩药业有限公司 | 2019-03-22 | — | — | CN | claimed |
| US-20170354644-A1 | Polymorphic Forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and Salts Thereof | CIPLA LIMITED (IN) | 2017-12-14 | — | — | US | claimed |
| WO-2016079697-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF DACLATASVIR DIHYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-26 | — | — | WO | claimed |
| WO-2016075588-A1 | STABLE AMORPHOUS DACLATASVIR DIHYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-19 | — | — | WO | claimed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2049522-A2 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | claimed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | claimed |
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | disclosed |
| US-20200346182-A1 | MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-11-05 | — | — | US | disclosed |
| CN-109503557-A | A kind of industrialized preparing process of his Wei key intermediate of Dacca | 常州吉恩药业有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-109503557-A | A kind of industrialized preparing process of his Wei key intermediate of Dacca | 常州吉恩药业有限公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3321263-A2 | COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2018-05-16 | — | — | EP | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | CYCS, COASY, CAT | MAPK13 1700/4885MAPK12 2089/4885MAPK11 1714/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAPK13 3291/4885MAPK12 3437/4885MAPK11 3947/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAPK13 3291/4885MAPK12 3437/4885MAPK11 3947/4885 |
| US-20170354644-A1 | Polymorphic Forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and Salts Thereof | MECP2, CPS1, MAT2A | MAPK13 3977/4885MAPK12 4392/4885MAPK11 3400/4885 |
| US-20200346182-A1 | MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF | CYCS, COASY, CAT | MAPK13 1730/4885MAPK12 2115/4885MAPK11 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.